Vorteile für Enzalutamid beim Prostatakarzinom
Crossref DOI link: https://doi.org/10.1007/s15015-016-2548-4
Published Online: 2016-05-06
Published Print: 2016-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Müller, Thomas
Text and Data Mining valid from 2016-05-01